Results 141 to 150 of about 141,799 (351)

Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether weight‐loss interventions are associated with obesity‐associated cancers (OAC) in individuals with overweight/obesity and type 2 diabetes (T2D). Materials and Methods This retrospective cohort study utilised the TriNetX federated research network.
Testimony Ipaye   +7 more
wiley   +1 more source

Comparative efficacy of sleeve gastrectomy with fundoplication versus standard sleeve gastrectomy in obesity and gastroesophageal reflux disease: A randomised trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This randomised controlled trial compared the efficacy of modified laparoscopic sleeve gastrectomy with fundoplication (LSGFD) versus standard laparoscopic sleeve gastrectomy (LSG) in achieving weight loss and alleviating gastroesophageal reflux disease (GERD) in patients with obesity.
Pierdiwasi Maimaitiyusupu   +5 more
wiley   +1 more source

Pre‐conception weight loss interventions in women with polycystic ovary syndrome and the effect on perinatal outcomes: A quantitative synthesis of surrogate outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Polycystic ovary syndrome (PCOS) guidelines recommend weight optimisation to improve anthropometric, metabolic and androgenic complications, but data is lacking for pregnancy outcomes. Materials and Methods We aimed to assess which weight loss interventions improve pregnancy outcomes for women with PCOS and overweight or obesity.
Amelia Fernandes   +2 more
wiley   +1 more source

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Semaglutide, a GLP‐1 receptor agonist, has shown efficacy in promoting weight loss. However, limited data exist on its impact on lean mass, muscle function, and metabolic adaptations. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4 mg).
Mathieu Alissou   +18 more
wiley   +1 more source

Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Metabolic bariatric surgery (MBS) improves histological endpoints in steatotic liver disease (SLD), but data on longer‐term clinical outcomes in this population are scarce. Here, we assessed the impact of MBS on hepatic and extrahepatic morbidity and mortality in individuals with SLD.
Weronika Stupalkowska   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy